Stock Events

Stock Events

Achilles Therapeutics 

€0.75
0
-€0.02-2.61% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
1.35
52W Low
1.35
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 698.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.29B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Achilles Therapeutics' cell therapy approach for cancer treatment.
Intellia Therapeutics
NTLA
Mkt Cap1.68B
Intellia Therapeutics is a leading developer of CRISPR gene editing, directly competing in the innovative treatment space including cancer.
Editas Medicine
EDIT
Mkt Cap304.49M
Editas Medicine operates in the CRISPR gene editing sector, offering potential competitive technologies for cancer therapy.
Allogene Therapeutics
ALLO
Mkt Cap786.66M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, which are in direct competition with Achilles' autologous cell therapy approach.
Gilead Sciences
GILD
Mkt Cap163.06B
Gilead Sciences, through its acquisition of Kite Pharma, has become a major player in the cell therapy space for cancer, competing with Achilles' therapies.

About

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Iraj Ali Ph.D.
Employees
204
Country
United Kingdom
ISIN
US00449L1026

Listings

MU
DE
698.MU
STU
DE
698.STU

0 Comments

Share your thoughts

FAQ

What is Achilles Therapeutics stock price today?▼
The current price of 698.STU is €0.75 EUR — it has decreased by -2.61% in the past 24 hours. Watch Achilles Therapeutics stock price performance more closely on the chart.
What is Achilles Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Achilles Therapeutics stocks are traded under the ticker 698.STU.
Is Achilles Therapeutics stock price growing?▼
698.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Achilles Therapeutics has showed a +0% increase.
How many employees does Achilles Therapeutics have?▼
As of May 11, 2026, the company has 204 employees.
In which sector is Achilles Therapeutics located?▼
Achilles Therapeutics operates in the Other sector.
When did Achilles Therapeutics complete a stock split?▼
Achilles Therapeutics has not had any recent stock splits.
Where is Achilles Therapeutics headquartered?▼
Achilles Therapeutics is headquartered in London, United Kingdom.